M
MBX Biosciences
Advancing potential breakthrough medicines for endocrine diseases of substantial medical need
About MBX Biosciences
MBX Biosciences is a clinical-stage biopharmaceutical company that specializes in the discovery and development of therapies for endocrine and metabolic diseases. The company's approach is centered around its proprietary Precision Endocrine Peptide™ (PEP™) platform, which enables the creation of novel peptide-based drug candidates.
Operating in the biopharmaceutical sector, MBX Biosciences focuses on conditions with unmet medical needs. The company's business model involves advancing its therapeutic candidates through the clinical trial process. As a clinical-stage company, its primary activities include research and development, conducting clinical trials to establish the safety and efficacy of its drug candidates, and seeking regulatory approval. The company went public with an IPO on September 13, 2024, and its stock is traded under the ticker MBX. Its revenue generation model is typical for a biopharmaceutical company at this stage, relying on investment capital to fund its R&D efforts. Future revenue will be dependent on the successful commercialization of its products, which may involve partnerships or licensing agreements with larger pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2018
- Headquarters
- Carmel, United States
- Listing
- IPO 2024
- Employees
- 78
- Open positions
- 17
- Dealroom signal
- 92.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Metabolism, Endocrinology, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma, DT and LS
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Sep 2025 | $200M | — | Undisclosed | ↗ |
| IPOOther financing | Sep 2024 | $188M | $188M | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$98M | — |
| 2025 | $0 | — | −$98M | — |
| 2024 | $0 | — | −$68M | — |
| 2023 | $0 | — | −$32M | — |
| 2022 | $0 | — | −$25M | — |
Growth signals
Latest recorded traffic for MBX Biosciences is 13K monthly website visits, up 8.3% over the last three months. MBX Biosciences's team grew 13% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Frazier Healthcare Partners
NEA- TPTwilight Venture Partners
BioCrossroads
OrbiMed
Wellington Management
Norwest Venture Partners
RA Capital Management
Series B and later4 investors entered at this stage
Deep Track Capital
Driehaus Capital Management
T. Rowe Price
Frazier Life Sciences
Other known investors1 additional known investor
Indiana University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about MBX Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MBX Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.